MedPath

Quinagolide

Generic Name
Quinagolide
Drug Type
Small Molecule
Chemical Formula
C20H33N3O3S
CAS Number
87056-78-8
Unique Ingredient Identifier
80Q9QWN15M
Background

Quinagolide is a non-ergot-derived selective dopamine D2 receptor agonist used for the treatment of elevated levels of prolactin or hyperprolactinaemia. Hyperprolalctinaemia is associated with gonadal dysfunction, including infertility and reduced libido, as well as long-term complications such as osteoporosis . Newer dopamine receptor agonists such as quinagolide and Cabergoline are shown to effectively inhibit prolactin secretion with improved efficacy over Bromocriptine. These drugs are effective in patients who are intolerant or resistant to Bromocriptine. Quinagolide exists as a racemate and its relevant clinical activity is mediated predominantly by the (-) enantiomer. It is typically present in the hydrochloride salt form and is marketed as oral tablets under the brand name Norprolac contained as a racemate. Quinagolide is currently available in several countries including Canada, but not approved for treatment in the United States.

Indication

用于治疗伴有高泌乳素血症的帕金森病,血催乳激素过多症(原发的或者是因分泌催乳激素的垂体微小腺瘤或巨腺瘤),也用于治疗肢端肥大症。

Associated Conditions
Hyperprolactinemia, Idiopathic Hyperprolactinemia

Quinagolide Vaginal Ring on Lesion Reduction Assessed by MRI in Women With Endometriosis/Adenomyosis

Phase 2
Completed
Conditions
Endometriosis
Interventions
First Posted Date
2018-11-21
Last Posted Date
2023-08-07
Lead Sponsor
Ferring Pharmaceuticals
Target Recruit Count
67
Registration Number
NCT03749109
Locations
🇩🇰

Gyneacology Rigshospitalet, Copenhagen, Denmark

🇵🇱

Gabinet Lekarski Specjalistyczny SONUS, Warsaw, Poland

🇵🇱

Specjalistyczny Gabinet Lekarski, Warsaw, Poland

and more 8 locations

Randomized Trial Assessing Quinagolide Vaginal Ring for Endometriosis-related Pain

Phase 2
Completed
Conditions
Endometriosis-related Pain
Interventions
First Posted Date
2018-10-02
Last Posted Date
2023-08-18
Lead Sponsor
Ferring Pharmaceuticals
Target Recruit Count
22
Registration Number
NCT03692403
Locations
🇺🇸

Johns Hopkins Outpatient Center, Baltimore, Maryland, United States

🇺🇸

Northwestern Memorial Hospital, Chicago, Illinois, United States

🇺🇸

Arkansas Primary Care Clinic, Little Rock, Arkansas, United States

and more 40 locations

Tolerability of Quinagolide in a Dose-titration Regimen in Oocyte Donors at Risk of Developing Ovarian Hyperstimulation Syndrome

Phase 2
Completed
Conditions
Ovarian Hyperstimulation Syndrome
Interventions
First Posted Date
2008-04-23
Last Posted Date
2009-09-17
Lead Sponsor
Instituto Valenciano de Infertilidad, IVI VALENCIA
Target Recruit Count
30
Registration Number
NCT00665041
Locations
🇪🇸

Instituto Valenciano de Infertilidad, Valencia, Spain

Study Assessing the Effect of 3-week Treatment With One of Three Oral Doses of Quinagolide

Phase 2
Completed
Conditions
Ovarian Hyperstimulation Syndrome
Interventions
First Posted Date
2006-05-25
Last Posted Date
2011-05-19
Lead Sponsor
Ferring Pharmaceuticals
Target Recruit Count
182
Registration Number
NCT00329693
Locations
🇪🇸

IVI Bilbao, Paseo Landabarri, 1, Leioa-Bizkaia, Spain

🇪🇸

IVI Sevilla, Avda. República Argentina, 58, Sevilla, Spain

🇪🇸

IVI Barcelona, Ronda General Mitre, 14, Barcelona, Spain

and more 4 locations
© Copyright 2025. All Rights Reserved by MedPath